Plasma and cellular fibronectin: distinct and independent functions during tissue repair.

To WS, Midwood KS. · 2011

Read Plasma and cellular fibronectin: distinct and independent functions during tissue repair. by To WS, Midwood KS. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3182887.txt.

Introduction

Wing To and Kim Midwood reviewed the two lives of a versatile repair protein in a 2011 paper in Fibrogenesis and Tissue Repair. Fibronectin circulates dissolved in blood and is also built locally by cells into a fibrous mesh. During healing, the blood form joins the early clot, helping platelets seal the wound.

Cell-made fibronectin then takes over as cells migrate in, assembling a three-dimensional scaffold that is far more than packing material: it directs cell behaviour throughout repair. Assembly follows a strict stepwise process with many regulators. When assembly runs wild, the same mesh drives fibrosis, the stiff scarring that ruins organs. Understanding its controls, the authors argue, may yield therapies that keep repair on the healthy side of that switch.

Catalog record

CREATORTo WS, Midwood KS.
YEAR2011
COLLECTIONPAPERS
FORMATTXT
FILE SIZE96 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3182887

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Plasma and cellular fibronectin: distinct and independent functions during tissue repair By Wing S To, Kim S Midwood Published in: Fibrogenesis & Tissue Repair DOI: 10.1186/1755-1536-4-21 ABSTRACT Abstract Fibronectin (FN) is a ubiquitous extracellular matrix (ECM) glycoprotein that plays vital roles during tissue repair. The plasma form of FN circulates in the blood, and upon tissue injury, is incorporated into fibrin clots to exert effects on platelet function and to mediate hemostasis. Cellular FN is then synthesized and assembled by cells as they migrate into the clot to reconstitute damaged tissue. The assembly of FN into a complex three-dimensional matrix during physiological repair plays a key role not only as a structural scaffold, but also as a regulator of cell function during this stage of tissue repair. FN fibrillogenesis is a complex, stepwise process that is strictly regulated by a multitude of factors. During fibrosis, there is excessive deposition of ECM, of which FN is one of the major components. Aberrant FN-matrix assembly is a major contributing factor to the switch from normal tissue repair to misregulated fibrosis. Understanding the mechanisms involved in FN assembly and how these interplay with cellular, fibrotic and immune responses may reveal targets for the future development of therapies to regulate aberrant tissue-repair processes. INTRODUCTION Fibronectin (FN) is a ubiquitous and essential component of the extracellular matrix (ECM). It functions both as a regulator of cellular processes and an important scaffolding protein to maintain and direct tissue organization and ECM composition. During tissue repair, the body acts in a series of tightly regulated steps to rapidly reconstitute damaged tissue: the formation of a fibrin clot acts as the platform for granulation tissue assembly, with subsequent contraction and remodeling of the ECM to reform normal tissue [1,2]. Different forms of FN play differential and temporally discrete roles during tissue repair. Plasma FN and cellular FN possess distinct structures and rates of assembly into three-dimensional matrices. In this paper, we discuss the differences in the structure of plasma and cellular FN, and their roles during the different stages of tissue repair. We summarize current theories of how FN is assembled into a three-dimensional matrix, and how this process is regulated. Understanding this complex matrix-assembly process may highlight potential targets for therapeutic advancement in the treatment of aberrant tissue-repair conditions. Structure of fibronectin isoforms FN is a multi-domain glycoprotein composed of an array of multiple repeated modular structures: twelve FN type I repeats (FNI), two FN type II repeats (FNII), fifteen constitutively expressed and two alternatively spliced (in this paper, referred to as EIIIA and EIIIB) FN type III (FNIII) repeats, and a non-homologous variable (V) or type III connecting segment (IIICS) region. The multimodular structure and intermodular regions allow flexibility of the FN molecule, which is involved in regulating its function [3-8]. These modules are organized into functional domains, including the N-terminal 70-kDa domain (FNI1-9), the 120-kDa central binding domain (CBD; FNIII1-12) and the heparin-binding domain HepII (FNIII12-14). The specific domains of FN can interact with multiple binding partners, including other ECM components and cell-surface receptors [9]. FN is secreted as a dimer maintained by two disulfide S-S bonds at its C-terminus [7,10-12] (Figure 1). [Figure: Fibronectin (FN) and FN fragments. FN is composed of a series of FNI repeats (dark-gray boxes), FNII repeats (circles), conserved FNIII repeats (light-gray boxes) and alternatively spliced FNIII repeats (EDA).] Plasma fibronectin Plasma FN is synthesized by hepatocytes and secreted into the blood plasma, where it circulates at 300-400 μg/ml [13] in a soluble, compact, inactive form. In soluble plasma FN, only one subunit possesses a V domain, and the EIIIB and EIIIA modules are absent [14-16]. Only very low levels (1.3-1.4 μg/ml) of FN possessing the EIIIA and/or EIIIB modules (cellular FN) have been reported to circulate in the blood plasma [17], but blood plasma levels have been shown to increase after major trauma resulting in vascular tissue damage, after inflammation, and in diseases such as atherosclerosis, ischaemic heart disease and stroke [18-21]. Cellular fibronectin Cellular FN is synthesized by many cell types, including fibroblasts, endothelial cells, chondrocytes, synovial cells and myocytes [22]. Cellular FN is a mixture of FN isoforms. The alternative splicing of EIIIB and EIIIA and more complex splicing of the V or IIICS domain during transcription of cellular FN allows different isoforms of FN to be expressed in a tissue-dependent, temporally regulated, and cell-type-specific manner [15,23-26]. In humans, 20 potential FN isoforms can be generated [27]. Increased expression of the EIIIA+ and EIIIB+ isoforms of FN are associated with areas of physiological or pathological tissue remodeling, including wound healing and tissue repair. The observed isoforms of FN, and their association with physiological or pathological conditions, are outlined in Table 1. These isoforms modulate the properties of the ECM, and affect cellular processes. [Table: Cellular fibronectin (FN) isoforms reported during physiological and pathological conditions] The orientation and rotational interdomain flexibilities of FNIII modules are known to be affected by neighboring domains, so the inclusion or exclusion of alternatively spliced domains may change the global conformation of FN, affecting the presentation of FNIII loop structures and binding sequences to modulate FN-cell signaling and FN-FN interactions during matrix assembly [9,28-33]. The structural composition of the different FN isoforms are important, as they play distinct roles in early and late wound-healing events [16]. Fibronectin in early wound-healing responses Plasma FN is a major component of the fibrin clot. Multiple mechanisms allow FN to be incorporated into the fibrin matrix. FN can interact via non-covalent interactions with fibrin via its FNI1-5 and FNI10-12 domains [34]. FN is also covalently crosslinked to fibrin by activation of the blood coagulation cascade involving activated Factor XIIIa (plasma transglutaminase or coagulation factor XIII) [2,14,16,35]. This crosslinks FN via glutamine residues within its N-terminus [36] to the fibrin α chains via ε-(γ-glutamyl) lysine cross links [37]. Furthermore, plasma FN can also be bound and then assembled into a high-molecular-weight multimeric matrix on the platelet surface. Platelet activation by thrombin induces increased cell-surface expression of the major platelet integrin αIIbβ3, which binds and assembles FN via a fibrin-independent mechanism [38-44]. Platelets also express a lower number of α5β1 and αvβ3 receptors on their surface, which mediate platelet adhesion [45]. Aggregated platelets can also assemble FN via a fibrin-dependent pathway [44]. The polymerization of fibrin into a three-dimensional network has been shown to be essential for FN assembly, as the γ chain of unprocessed fibrinogen signals via αIIbβ3 to inhibit this process [38]. Platelet-producing megakaryocytes endocytose and pinocytose FN from the plasma, which becomes packaged into the α granules of platelets [46]. This has been shown to involve the αIIbβ3 integrin; mice with a mutation in the gene encoding the fibrinogen γ chain (which prevents fibrinogen interactions with αIIbβ3), von Willebrand factor null mice, and fibrinogen null mice show increased FN levels in their α granules [47-49]. Upon platelet activation, FN is released from α granules in a process called degranulation. The FN released from platelets can also assemble on the surface of platelets [42,46,50]. FN incorporation into the fibrin matrix is important for various platelet functions, including adhesion, migration and aggregation (Figure 2) [16,36,38,45,46,48,49,51-98]. However, in vitro fibrin assembly was shown to be unaffected by a complete

Read the complete text